Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?
Authors: Ji Guang Wang
Yook Chin Chia
Chen Huan Chen
Sungha Park
Satoshi Hoshide
Naoko Tomitani
Tomoyuki Kabutoya
Jinho Shin
Yuda Turana
Arieska Ann Soenarta
Jam Chin Tay
Peera Buranakitjaroen
Jennifer Nailes
Huynh Van Minh
Saulat Siddique
Jorge Sison
Guru Prasad Sogunuru
Apichard Sukonthasarn
Boon Wee Teo
Narsingh Verma
Yu Qing Zhang
Tzung Dau Wang
Kazuomi Kario
University Medicine and Pharmacy, Hue University
De La Salle Health Sciences Institute
Sunway University
Hanyang University Medical Center
Jichi Medical University
Yonsei University Health System
Shanghai Jiao Tong University School of Medicine
Madras Institute of Orthopaedics and Traumatology Hospitals
Kathmandu University
University of the East Ramon Magsaysay Memorial Medical Center
Fatima Memorial Hospital
Universitas Katolik Indonesia Atma Jaya
Universitas Indonesia
University of Malaya
Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Yong Loo Lin School of Medicine
National Taiwan University College of Medicine
King George's Medical University
Faculty of Medicine, Siriraj Hospital, Mahidol University
National Yang-Ming University, School of Medicine
Tan Tock Seng Hospital
Chiang Mai University
Keywords: Medicine
Issue Date: 1-Jan-2020
Citation: Journal of Clinical Hypertension. (2020)
Abstract: © 2020 Wiley Periodicals, Inc. The new Chinese hypertension guideline comprehensively covers almost all major aspects in the management of hypertension. In this new guideline, hypertension remains defined as a systolic/diastolic blood pressure of at least 140/90 mm Hg. For risk assessment, a qualitative approach is used similarly as in previous Chinese guidelines according to the blood pressure level and the presence or absence of other risk factors, target organ damage, cardiovascular complications, and comorbid diseases. The therapeutic target is 140/90 mm Hg in general, and if tolerated, especially in high-risk patients, can be more stringent, that is, 130/80 mm Hg. However, a less stringent target, that is, 150/90 mm Hg, is used in the younger (65-79 years, if tolerated, 140/90 mm Hg) and older elderly (≥80 years). Five classes of antihypertensive drugs, including β-blockers, can be used either in initial monotherapy or combination. The guideline also provided information on the management of hypertension in several special groups of patients and in the presence of secondary causes of hypertension. To implement the guideline recommendations, several nationwide hypertension control initiatives are being undertaken with new technology. The new technological platforms hopefully will help improve the management of hypertension and generate scientific evidence for future hypertension guidelines, including a possible Asian hypertension guideline in the near future.
ISSN: 17517176
Appears in Collections:Scopus 2020

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.